CSRxP

The Hill

The Hill: FDA approves cholesterol drug with $15,000 yearly price tag

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but its price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years,” John Rother, president of the National Coalition on Health Care, said in a statement.

Read more
csrxp

PRESS STATEMENT: FDA Approves Praluent, New Cholesterol-Lowering Treatment

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.”

Read more

UAW Retiree Medical Benefits Trust Joins Campaign for Sustainable Rx Pricing

FOR IMMEDIATE RELEASE Contact: Kara Batt (571) 239-6547 kbatt@nchc.org #### May 20, 2015 — UAW Retiree Medical Benefits Trust (the “Trust”), the largest non-governmental payor of […]

Read more